Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.64+0.02 (+0.19%)
Close on Nov 13, 2026Market cap $895.05MP/E –Yield –
Corvus Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Corvus Pharmaceuticals's enterprise value was $749.67M on Nov 11, 2026, against $619.13M a year earlier. Over the last 5 years it ranged from -$21.93M to $1.48B, with a median of $103.93M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $749.67M | +47.2% |
| 2025 | Dec 31, 2025 | $509.35M | +73.8% |
| 2024 | Dec 31, 2024 | $293.10M | +441.7% |
| 2023 | Dec 29, 2023 | $54.11M | – |
| 2022 | Dec 30, 2022 | -$10.03M | -128.0% |
| 2021 | Dec 31, 2021 | $35.88M | -26.0% |
| 2020 | Dec 31, 2020 | $48.49M | -34.1% |
| 2019 | Dec 31, 2019 | $73.57M | – |
| 2018 | Dec 31, 2018 | -$15.13M | -112.9% |
| 2017 | Dec 29, 2017 | $117.28M | -23.8% |
| 2016 | Dec 30, 2016 | $153.94M | – |
See a number that looks wrong?